Frankfurt - Delayed Quote EUR

Gilead Sciences, Inc. (GIS.F)

90.73

-2.78

(-2.97%)

As of 8:00:37 AM GMT+2. Market Open.

Gilead Sciences posts mixed Q1 results

Gilead Sciences (GILD) reported first quarter earnings that topped analyst estimates, but its revenue in the quarter fell short. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above.  To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.

Yahoo Finance Video 9 hours ago

GILD
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 7 hours ago

GILD
Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.

Executives told Barron’s that the company is well-positioned to handle potential pharmaceutical tariffs.

Barrons.com 8 hours ago

GILD
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 9 hours ago

GILD
Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.

StockStory 10 hours ago

GILD
Gilead Dives After Its Bread-And-Butter Drug Misses Sales Forecasts

Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell in late action.

Investor's Business Daily 10 hours ago

GILD
Gilead: Q1 Earnings Snapshot

Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, came to $1.81 per share. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.82 per share.

Associated Press Finance 10 hours ago

GILD
Gilead posts profit, says HIV prevention drug on track for mid-June

(Reuters) -Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales. Adjusted earnings per share came in at $1.81, just ahead of the average analysts' estimate of $1.79, as compiled by LSEG. Gilead's in-line product sales, slight EPS beat and lower expenses were "positive," while the key catalyst for the company's shares will be a "clean and smooth approval" in the United States of lenacapavir for preventing HIV, said Jefferies analyst Michael Yee.

Reuters 10 hours ago

GILD
Gilead Sciences Announces First Quarter 2025 Financial Results

FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.

Business Wire 10 hours ago

GILD
The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are part of the Zacks top Analyst Blog.

Zacks yesterday

ABBV

SNY

CELG-RT
Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what you need to know.

StockStory yesterday

GILD
Gilead reports topline data from Phase III trial of Trodelvy combo therapy

In the trial, the primary endpoint was met, demonstrating a PFS improvement against standard treatment.

Clinical Trials Arena 2 days ago

GILD
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

We recently published a list of the 11 Cheap NASDAQ Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against other cheap NASDAQ stocks. On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an […]

Insider Monkey 2 days ago

GILD
Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Investing.com -- Cantor Fitzgerald initiated or transferred coverage on 10 large-cap U.S. biopharma stocks in a note Tuesday, highlighting a selective approach that favors dominant franchises with strong growth visibility and limited exposure to policy headwinds.

Investing.com 2 days ago

ABBV

LLY

GILD
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.

Zacks 2 days ago

ABBV

CELG-RT

SNY
Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, highlighting significant benefits in treating metastatic triple-negative breast cancer. This development may have supported the company's 12% price gain in the last quarter, complementing broader oncology advances. Despite a turbulent broader market impacted by global trade tension and inflationary pressures, Gilead's progress in clinical research, financial performance, and...

Simply Wall St. 3 days ago

GILD
Why Investors Need to Take Advantage of These 2 Medical Stocks Now

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks 3 days ago

GILD

CVS
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

FOSTER CITY, Calif., April 21, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) significantly improved progression-free survival (PFS) compared to Keytruda and chemotherapy in patients with inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (mTNBC) whose tumors express PD-L1 (CPS ≥ 10). The st

Business Wire 3 days ago

GILD
Here's Why Gilead Sciences (GILD) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 6 days ago

GILD
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings

Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks 6 days ago

GILD

Performance Overview

Return	GIS.F	S&P 500 (^GSPC)
YTD	+1.77%	-6.75%
1-Year	+54.76%	+8.64%
3-Year	+77.24%	+27.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Gilead Sciences, Inc. (GIS.F)

Gilead Sciences posts mixed Q1 results

Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say

Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.

Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates

Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates

Gilead Dives After Its Bread-And-Butter Drug Misses Sales Forecasts

Gilead: Q1 Earnings Snapshot

Gilead posts profit, says HIV prevention drug on track for mid-June

Gilead Sciences Announces First Quarter 2025 Financial Results

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi

Gilead Sciences (GILD) To Report Earnings Tomorrow: Here Is What To Expect

Gilead reports topline data from Phase III trial of Trodelvy combo therapy

Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds?

Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy

Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?

Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Here's Why Gilead Sciences (GILD) is a Strong Value Stock

What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings

Performance Overview